Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
The STEP-HFpEF trial randomised 529 patients with obesity (BMI 30 kg/m 2 ), HFpEF (left ventricular ejection fraction [LVEF] 45%) and New York Heart Association (NYHA) Class II symptoms to once-weekly subcutaneous semaglutide 2.4 mg or placebo
Evidence behind microdosing GLP-1 drugs and other off-ramping techniques is still limited all the more reason to talk to your care provider before your last dose
It is not prescribed for weight loss
The choice depends on curve location, severity, and patient lifestyle factors
The unamidated free-carboxylic-acid form binds with substantially reduced affinity and produces a different downstream signalling profile in cell-based assays
US$ 20.40
US$ 21.64
US$ 21.46
US$ 24.38
US$ 29.29
